Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 5 of 5 for “"NI margin"”.
-
Non-Inferiority Margin Setting from Indirect Comparison
Introduction: Non-inferiority trials (NI) test the efficacy of an experimental treatment in comparison to an active-controlled treatment and indirectly with the historical placebo to demonstrate that the new treatment is no worse than the active comparator. Setting the NI margin depends on the …
-
HOW ARE NON-INFERIORITY MARGINS SELECTED IN NON-INFERIORITY TRIALS AND HOW DO THEY VARY WITHIN AND ACROSS FOUR MAJOR DISEASE DOMAINS? – A REVIEW
… approaches to the selection of non-inferiority (NI) margins in non-inferiority trials and to explore the extent of variation in the selection of NI margins; Methods: Non-inferiority trials in stroke, cardiovascular disease, infectious disease and diabetes were searched and screened for inclusion …
-
Impact of Historical Borrowing in Bayesian Non-Inferiority Trial with Binary Data
Non-inferiority (NI) trials have gained popularity within the last decades for comparative effectiveness research. Three-arm NI trials design, whenever feasible, is recommended as both non-inferiority and the assay sensitivity (AS) of the treatment can be directly evaluated within the trial. …
-
An Evaluation of Flexible Summary Measures for the Comparison of Binary Outcomes in Non-Inferiority Trials
In clinical trials, the comparison of binary outcomes between two independent treatment groups is most commonly measured by either relative or absolute differences between outcome rates. In the setting of a non-inferiority (NI) trial, an NI margin corresponding to one of these measures is defined …
-
Bayesian Approach to Three Arm Non-Inferiority Clinical Trial Using Negative Binomial Endpoint
Non inferiority clinical trials have gained immense popularity within the last decades. Such trials are designed to demonstrate that a new experimental drug is not unacceptably worse than an active control by more than a pre-specified margin. The experimental treatment may not be as good as the …